CCND1 and prostate cancer: Nexrutine, a Phellodendron amurense bark methanol extract, was found to inhibit prostate cancer cell proliferation through modulation of AKT and cAMP-responsive element binding protein (CREB)-mediated signaling pathway, and that Nexrutine activates cyclin D1, which prevents the progression of prostate cancer [27].